Vincent Chen1,2, Shigeki Umemura1, Yumin Han3, Renuka Raman3, Robin Tucker1, Joeffrey Chahine1, In-Kyu Kim1, Christoph Schatz4, Sabine Zitzmann-Kolbe4, Anette Sommer4,5, Masanori Onda6, Trevor Lee3, Yongfeng He3, Giuseppe Giaccone7,8. 1. Georgetown University Medical Center, Washington, DC, USA. 2. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 3. Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. 4. Bayer AG, Pharmaceuticals, Berlin, Germany. 5. Pfizer Worldwide Research, Development, and Medicine, Berlin, Germany. 6. National Cancer Institute, Bethesda, MD, USA. 7. Georgetown University Medical Center, Washington, DC, USA. gig4001@med.cornell.edu. 8. Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA. gig4001@med.cornell.edu.
Abstract
BACKGROUND: Thymic epithelial tumours (TETs) are rare tumours comprised of thymomas and thymic carcinoma. Novel therapies are needed, especially in thymic carcinoma where the 5-year survival rate hovers at 30%. Mesothelin (MSLN), a surface glycoprotein that is cleaved to produce mature MSLN (mMSLN) and megakaryocyte potentiating factor (MPF), is expressed in limited tissues. However, its expression is present in various cancers, including thymic carcinoma, where it is expressed in 79% of cases. METHODS: We utilised flow cytometry, in vitro cytotoxicity assays, and an in vivo xenograft model in order to demonstrate the ability of the MSLN targeting antibody-drug conjugate (ADC) anetumab ravtansine (ARav) in inhibiting the growth of thymic carcinoma. RESULTS: Thymoma and thymic carcinoma cell lines express MSLN, and anetumab, the antibody moiety of ARav, was capable of binding MSLN expressing thymic carcinoma cells and internalising. ARav was effective at inhibiting the growth of thymic carcinoma cells stably transfected with mMSLN in vitro. In vivo, 15 mg/kg ARav inhibited T1889 xenograft tumour growth, while combining 7.5 mg/kg ARav with 4 mg/kg cisplatin yielded an additive effect on inhibiting tumour growth. CONCLUSIONS: These data demonstrate that anetumab ravtansine inhibits the growth of MSLN positive thymic carcinoma cells in vitro and in vivo.
BACKGROUND: Thymic epithelial tumours (TETs) are rare tumours comprised of thymomas and thymic carcinoma. Novel therapies are needed, especially in thymic carcinoma where the 5-year survival rate hovers at 30%. Mesothelin (MSLN), a surface glycoprotein that is cleaved to produce mature MSLN (mMSLN) and megakaryocyte potentiating factor (MPF), is expressed in limited tissues. However, its expression is present in various cancers, including thymic carcinoma, where it is expressed in 79% of cases. METHODS: We utilised flow cytometry, in vitro cytotoxicity assays, and an in vivo xenograft model in order to demonstrate the ability of the MSLN targeting antibody-drug conjugate (ADC) anetumab ravtansine (ARav) in inhibiting the growth of thymic carcinoma. RESULTS: Thymoma and thymic carcinoma cell lines express MSLN, and anetumab, the antibody moiety of ARav, was capable of binding MSLN expressing thymic carcinoma cells and internalising. ARav was effective at inhibiting the growth of thymic carcinoma cells stably transfected with mMSLN in vitro. In vivo, 15 mg/kg ARav inhibited T1889 xenograft tumour growth, while combining 7.5 mg/kg ARav with 4 mg/kg cisplatin yielded an additive effect on inhibiting tumour growth. CONCLUSIONS: These data demonstrate that anetumab ravtansine inhibits the growth of MSLN positive thymic carcinoma cells in vitro and in vivo.
Authors: Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel Journal: J Thorac Oncol Date: 2015-10 Impact factor: 15.609
Authors: Raffit Hassan; Steven J Cohen; Martin Phillips; Ira Pastan; Elad Sharon; Ronan J Kelly; Charles Schweizer; Susan Weil; Daniel Laheru Journal: Clin Cancer Res Date: 2010-10-29 Impact factor: 12.531
Authors: Sven Golfier; Charlotte Kopitz; Antje Kahnert; Iring Heisler; Christoph A Schatz; Beatrix Stelte-Ludwig; Anke Mayer-Bartschmid; Kerstin Unterschemmann; Sandra Bruder; Lars Linden; Axel Harrenga; Peter Hauff; Frank-Detlef Scholle; Beate Müller-Tiemann; Bertolt Kreft; Karl Ziegelbauer Journal: Mol Cancer Ther Date: 2014-04-08 Impact factor: 6.261
Authors: Dominic Fan; Seiji Yano; Hisashi Shinohara; Carmen Solorzano; Melissa Van Arsdall; Corazon D Bucana; Sen Pathak; Ewa Kruzel; Roy S Herbst; Amir Onn; Jennifer S Roach; Masanori Onda; Qing-cheng Wang; Ira Pastan; Isaiah J Fidler Journal: Mol Cancer Ther Date: 2002-06 Impact factor: 6.009
Authors: Raffit Hassan; Elad Sharon; Anish Thomas; Jingli Zhang; Alexander Ling; Markku Miettinen; Robert J Kreitman; Seth M Steinberg; Kevin Hollevoet; Ira Pastan Journal: Cancer Date: 2014-07-02 Impact factor: 6.921
Authors: Raffit Hassan; George R Blumenschein; Kathleen N Moore; Alessandro D Santin; Hedy L Kindler; John J Nemunaitis; Shelly M Seward; Anish Thomas; Stella K Kim; Prabhu Rajagopalan; Annette O Walter; Dirk Laurent; Barrett H Childs; Nenad Sarapa; Cem Elbi; Johanna C Bendell Journal: J Clin Oncol Date: 2020-03-26 Impact factor: 44.544